United States patent US 9498423 describes a synergistic composition comprising of β – glucogallin (1-O-galloyl-β-D-glucose) or β – glucogallin and total gallates from Amla (Saberry®), concentrate of liquid endosperm of Cocos nucifera (Cococin®) and the selenopeptides (γ-L-glutamyl-Se-methyl-L-selenocysteine, and γ-L-glutamyl- L-selenomethionine) for maintaining the morphology and numbers of the dermal papilla cells when exposed to stress signals. The composition protects the dermal papilla cells from stress signals (UVB radiation), and the numbers of live dermal papilla cells are maintained at a level of 95% or more when the dermal papilla cells are exposed to UVB radiation levels ranging from 0.8 J/cm2 to 1.0 J/cm2. This composition has also been patented in Europe (EP2695603), Japan (JP6064274), New Zealand (NZ600307) and Russia (RU2606752).
Sabinsa’s cosmetic division has also received a patent in Europe (EP2461786) for a composition comprising β – glucogallin (1-O-galloyl-β-D-glucose) Amla (Saberry®) and concentrate of liquid endosperm of Cocos nucifera (Cococin®) for promoting hair growth. This composition also protects dermal papilla cells from UV rays. The invention has previously been granted a patent in in Australia (AU2010326651).
About Sabinsa Corporation:
Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 29 years, Sabinsa has brought to market more than 100 standardized botanical extracts, and privately funded clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full-time scientists conducting ongoing research in India and the United States, Sabinsa and parent company Sami Labs Ltd. continue to develop, patent and manufacture phytonutrients for the world market, with ingredients that are both Halal and Kosher. For more information, visit www.sabinsacosmetics.com